New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
11:19 EDTEGO, NAT, LUK, INSM, AMCCHigh option volume stocks: LUK AMCC INSM EGO NAT
News For LUK;AMCC;INSM;EGO;NAT From The Last 14 Days
Check below for free stories on LUK;AMCC;INSM;EGO;NAT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
16:58 EDTINSMJames Flynn reports 7.75% passive stake in Insmed
April 9, 2014
14:10 EDTLUKLeucadia CFO Joseph Orlando to retire for health reasons
Leucadia National Corporation announced that Joseph A. Orlando, its CFO, intends to retire by August 31 due to orthopedic health issues that require his attention. A search is underway to recruit Orlando’s successor.
April 8, 2014
12:00 EDTNATNordic American Tanker falls 9.8%
Subscribe for More Information
10:00 EDTNATNordic American Tanker falls 10.1%
Nordic American Tanker is down 10.1%, or 96c, to $8.50
09:00 EDTNATNordic American Tanker falls 10.5%
Subscribe for More Information
April 7, 2014
19:23 EDTNATNordic American Tanker 12M share Spot Secondary priced at $8.62
Subscribe for More Information
19:05 EDTNATOn The Fly: After Hours Movers
LOWER: Gigamon (GIMO), down 24% after cutting its first quarter revenue outlook, which the company attributed to one expected large transaction from an existing customer that did not materialize... James River Coal (JRCC), down 44% after filing for Chapter 11 bankruptcy... Trading lower after filing to sell stock were Nordic American Tanker (NAT), down 8.5% after filing to sell 10M common shares, and Voxeljet (VJET), down 4.7% after filing to sell 4M American Depository Shares, including 1M for selling holders.
16:02 EDTNATNordic American Tanker files to sell 10M shares of common stock
Subscribe for More Information
07:24 EDTINSMInsmed data likely supports accelerated approval in NTM, says Piper Jaffray
Piper Jaffray believes Insmed's data for Arikayce in nontuberculous mycobacteria is likely to support accelerated approval, especially if the relapse rate is modest. Piper says recent data for Arikayce has caused "considerable controversy" and it reiterates an Overweight rating on shares of Insmed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use